pSivida Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
EyePoint Inc (EYPT)
EyePoint Inc stock price live, this page displays NASDAQ EYPT stock exchange data. View the EYPT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the EyePoint Inc real time stock price chart below.
What Is the EyePoint Inc Stock Price Today?
The EyePoint Inc stock price today is 0.461.
What Is the Stock Symbol for EyePoint Inc?
The stock symbol for EyePoint Inc is "EYPT."
What Stock Exchange Does EyePoint Inc Trade On?
EyePoint Inc is listed and trades on the NASDAQ stock exchange.
Is EyePoint Inc a Good Stock to Buy?
Determining whether EyePoint Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EYPT quote. (ISIN: US30233G2093)
What Is the EyePoint Inc Stock Price Today?
The EyePoint Inc stock price today is 0.461.
What Is the Stock Symbol for EyePoint Inc?
The stock symbol for EyePoint Inc is "EYPT."
What Stock Exchange Does EyePoint Inc Trade On?
EyePoint Inc is listed and trades on the NASDAQ stock exchange.
Is EyePoint Inc a Good Stock to Buy?
Determining whether EyePoint Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EYPT quote. (ISIN: US30233G2093)
0.461
+0.021(+4.68%)
Real-time Data·
Fair Value
An estimate of a EyePoint's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.417
0.475
52 wk Range
0.403
19.110
Unusual trading volume
1/3
Fair Value
An estimate of a EyePoint's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.4170.475
52 wk Range
0.40319.110
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EYPT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a EyePoint's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
17.556
Upside
+3,708.15%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
5 Buy
8 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 17.556
(+3,708.15% Upside)
EyePoint Inc Earnings Call Summary for Q1/2026
- EyePoint missed Q1 2026 forecasts with EPS of -$0.99 vs. -$0.82 expected; revenue fell 97.1% YoY to $0.7M as deferred revenue recognition ended.
- Operating expenses rose 20.5% to $88M driven by Phase III trials for DURAVYU; net loss widened to $85M from $45M in Q1 2025.
- Company maintains $223M cash position expected to fund operations through Q4 2027 without additional financing needs.
- DURAVYU Phase III wet AMD data expected mid-2026; DME trial enrollment to complete Q3 2026 as company pursues first-in-class treatment status.
- Stock rose 2.28% to $14.064 despite earnings miss, reflecting investor optimism about clinical pipeline despite high cash burn and regulatory risks.
Last Updated: 06/05/2026, 14:52
Read Full TranscriptEarnings
Latest Release
Aug 05, 2026
EPS / Forecast
-1.09 / -0.94
Revenue / Forecast
507K / 383K
Compare EYPT to Peers and Sector
Metrics to compare | EYPT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEYPTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.1x | −2.0x | −0.3x | |
PEG Ratio | 0.00 | −0.02 | 0.00 | |
Price/Book | 0.2x | 1.5x | 2.6x | |
Price / LTM Sales | 13.3x | 1.9x | 2.9x | |
Upside (Analyst Target) | - | 51.2% | 62.0% | |
Fair Value Upside | Unlock | 23.2% | 9.5% | Unlock |
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the EyePoint (EYPT) Stock Price Today?
The EyePoint stock price today is 0.461 USD.
What Stock Exchange Does EyePoint Trade On?
EyePoint is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for EyePoint?
The stock symbol for EyePoint is "EYPT."
What Is the EyePoint (EYPT) Afterhours Price Today? (Afterhours variable test: 0.436) Current Date: Oct 20, 2026
After hours price: 0.436. After hours price change (units): -0.004. Price change percentage: -0.910%
What Is the EyePoint Market Cap?
As of today, EyePoint market cap is 39.830M USD.
What Is EyePoint's Earnings Per Share (TTM)?
The EyePoint EPS (TTM) is -3.76.
When Is the Next EyePoint Earnings Date?
EyePoint will release its next earnings report on Nov 04, 2026.
From a Technical Analysis Perspective, Is EYPT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has EyePoint Stock Split?
EyePoint has split 2 times.
What is the current trading status of EyePoint (EYPT)?
As of Oct 20, 2026, EyePoint (EYPT) is trading at a price of 0.461 USD, with a previous close of 0.440 USD. The stock has fluctuated within a day range of 0.417 USD to 0.475 USD, while its 52-week range spans from 0.403 USD to 19.110 USD.
What Is EyePoint (EYPT) Price Target According to Analysts?
The average 12-month price target for EyePoint is 17.556 USD, with a high estimate of 48 USD and a low estimate of 1 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +3,708.15% Upside potential.
What Is the EYPT Premarket Price?
EYPT's last pre-market stock price is 0.423 USD. The pre-market share volume is 1,560,000.000, and the stock has decreased by -0.017, or -3.860%.
What Is the EYPT After Hours Price?
EYPT's last after hours stock price is 0.436 USD, the stock has decreased by -0.004, or -0.910%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.